Quote:

---

We took the biggest problem I guess with the BLA and just wanted to turn things around and submit that and take care of that first with the FDA. So in talking with the FDA in the path there were problems with receptor occupancy assay and so we submitted a draft of our plan to them for receptor occupancy and they agreed and we're proceeding. We're thrilled this is one obstacle we've overcome - Dr. Chris Recknor

---